LOS ANGELES, June 16, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help guide cancer therapy selection, today announced the availability of new testing capabilities to advance cancer immunotherapy clinical development. The Immuno-Oncology assay, which runs on HTG Molecular's Edge System, is designed to measure the RNA expression of 26 commonly investigated immunotherapy related genes enabling screening for response to immunoregulatory pathways. The Iummo-Oncology test will be made available to all of Response Genetics' existing biopharmaceutical partners, and new potential partners, to aid in development of biomarker driven cancer immunotherapy clinical trials.
Help employers find you! Check out all the jobs and post your resume.
